Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Franck Morschhauser¹, Saurabh Dahiya^{2

3}, M Lia Palomba⁴, Alejandro Martin Garcia-Sancho⁵, Juan Luis Reguera Ortega⁶, John Kuruvilla⁷, Ulrich Jäger⁸, Guillaume Cartron⁹, Koji Izutsu¹⁰, Martin Dreyling¹¹, Brad Kahl¹², Hervé Ghesquieres¹³, Kirit Ardeshna¹⁴, Hideki Goto¹⁵, Anna Maria Barbui¹⁶, Jeremy S Abramson¹⁷, Peter Borchmann¹⁸, Isabelle Fleury¹⁹, Stephan Mielke²⁰, Alan Skarbnik²¹, Sven de Vos²², Manali Kamdar²³, Reem Karmali²⁴, Andreas Viardot²⁵, Thalia Farazi²⁶, Omotayo Fasan²⁷, James Lymp²⁸, Min Vedal²⁸, Rina Nishii²⁷, Ariel Avilion²⁸, Jessica Papuga²⁹, Jinender Kumar²⁷, Loretta J Nastoupil³⁰

Affiliations

¹ Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France. franck.morschhauser@chu-lille.fr.
² Stanford University School of Medicine, Stanford, CA, USA.
³ University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
⁴ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain.
⁶ Hospital Virgen del Rocío, Instituto de Biomedicina de la Universidad de Sevilla, Seville, Spain.
⁷ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
⁸ Medical University of Vienna, Vienna, Austria.
⁹ Montpellier University Hospital Center, UMR CNRS 5535, Montpellier, France.
¹⁰ National Cancer Center Hospital, Tokyo, Japan.
¹¹ LMU University Hospital, München, Germany.
¹² Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
¹³ Hôpital Lyon Sud, Lyon, France.
¹⁴ University College London Hospitals Biomedical Research Centre, London, UK.
¹⁵ Hokkaido University Hospital, Sapporo, Japan.
¹⁶ Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
¹⁷ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
¹⁸ Universität zu Köln, Köln, Germany.
¹⁹ Hôpital Maisonneuve - Rosemont, Montreal, Quebec, Canada.
²⁰ Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Karolinska ATMP Center, Stockholm, Sweden.
²¹ Novant Health Cancer Institute, Charlotte, NC, USA.
²² UCLA Santa Monica Medical Centre, Santa Monica, CA, USA.
²³ University of Colorado Cancer Center, Aurora, CO, USA.
²⁴ Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
²⁵ Department of Internal Medicine III, University Hospital, Ulm, Germany.
²⁶ Bristol Myers Squibb, Brisbane, CA, USA.
²⁷ Bristol Myers Squibb, Princeton, NJ, USA.
²⁸ Bristol Myers Squibb, Seattle, WA, USA.
²⁹ Bristol Myers Squibb, Boudry, Switzerland.
³⁰ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 38982297
PMCID: PMC11333276
DOI: 10.1038/s41591-024-03175-4

Published Erratum

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Franck Morschhauser et al. Nat Med. 2024 Aug.

. 2024 Aug;30(8):2374.

doi: 10.1038/s41591-024-03175-4.

Authors

Affiliations

¹ Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France. franck.morschhauser@chu-lille.fr.
² Stanford University School of Medicine, Stanford, CA, USA.
³ University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
⁴ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain.
⁶ Hospital Virgen del Rocío, Instituto de Biomedicina de la Universidad de Sevilla, Seville, Spain.
⁷ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
⁸ Medical University of Vienna, Vienna, Austria.
⁹ Montpellier University Hospital Center, UMR CNRS 5535, Montpellier, France.
¹⁰ National Cancer Center Hospital, Tokyo, Japan.
¹¹ LMU University Hospital, München, Germany.
¹² Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
¹³ Hôpital Lyon Sud, Lyon, France.
¹⁴ University College London Hospitals Biomedical Research Centre, London, UK.
¹⁵ Hokkaido University Hospital, Sapporo, Japan.
¹⁶ Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
¹⁷ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
¹⁸ Universität zu Köln, Köln, Germany.
¹⁹ Hôpital Maisonneuve - Rosemont, Montreal, Quebec, Canada.
²⁰ Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Karolinska ATMP Center, Stockholm, Sweden.
²¹ Novant Health Cancer Institute, Charlotte, NC, USA.
²² UCLA Santa Monica Medical Centre, Santa Monica, CA, USA.
²³ University of Colorado Cancer Center, Aurora, CO, USA.
²⁴ Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
²⁵ Department of Internal Medicine III, University Hospital, Ulm, Germany.
²⁶ Bristol Myers Squibb, Brisbane, CA, USA.
²⁷ Bristol Myers Squibb, Princeton, NJ, USA.
²⁸ Bristol Myers Squibb, Seattle, WA, USA.
²⁹ Bristol Myers Squibb, Boudry, Switzerland.
³⁰ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 38982297
PMCID: PMC11333276
DOI: 10.1038/s41591-024-03175-4

No abstract available

PubMed Disclaimer

Erratum for

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Morschhauser F, et al. Nat Med. 2024 Aug;30(8):2199-2207. doi: 10.1038/s41591-024-02986-9. Epub 2024 Jun 3. Nat Med. 2024. PMID: 38830991 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Affiliations

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources